Document:

THIS
      WARRANT AND THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER
      THE
      SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE, AND
      MAY
      NOT BE TRANSFERRED IN VIOLATION OF SUCH ACT, THE RULES AND REGULATIONS
      THEREUNDER OR ANY STATE SECURITIES LAWS OR THE PROVISIONS OF THIS
      WARRANT.

     

    No.
      of
      Shares of Common Stock: 100,000

     

    WARRANT

     

    To
      Purchase Common Stock of

     

    BIOMETRX,
      INC.

     

    THIS
      IS
      TO CERTIFY THAT Interactive Resources Group, Inc. (the “Holder”), or its
      registered assigns, is entitled, at any time from the Warrant Issuance Date
      (as
      hereinafter defined) to the Expiration Date (as hereinafter defined), to
      purchase from BIOMETRX, INC., a Delaware corporation (the “Company”), One
      Hundred Thousand (100,000) shares of Common Stock (as hereinafter defined and
      subject to adjustment as provided herein), in whole or in part, including
      fractional parts, at a purchase price per share equal to $_____ subject to
      any
      adjustments made to such amount pursuant to Section 4 hereto) on the terms
      and
      conditions and pursuant to the provisions hereinafter set forth. 

     

    
      	
              1.

            	
              DEFINITIONS

            

    

     

    As
      used
      in this Warrant, the following terms have the respective meanings set forth
      below:

     

    “Additional
      Shares of Common Stock” shall mean all shares of Common Stock issued by the
      Company after the Closing Date, other than Warrant Stock.

     

    “Book
      Value” shall mean, in respect of any share of Common Stock on any date herein
      specified, the consoli-dated book value of the Company as of the last day of
      any
      month immediately preceding such date, divided by the number of Fully Diluted
      Outstanding shares of Common Stock as deter-mined in accordance with GAAP
      (assuming the payment of the exercise prices for such shares) by a firm of
      independent certified public account-ants of recognized national standing
      selected by the Company and reasonably acceptable to the Holder.

     

    “Business
      Day” shall mean any day that is not a Saturday or Sunday or a day on which banks
      are required or permitted to be closed in the State of New York.

     

    “Commission”
      shall mean the Securities and Exchange Commission or any other federal agency
      then administering the Securities Act and other federal securities
      laws.

     

    “Common
      Stock” shall mean (except where the context otherwise indicates) the Common
      Stock, par value $.001 per share, of the Company as constituted on the Closing
      Date, and any capital stock into which such Common Stock may there-after be
      changed, and shall also include (i) capital stock of the Company of any
      other class (regardless of how denomi-nated) issued to the holders of shares
      of
      Common Stock upon any reclassification thereof which is also not preferred
      as to
      dividends or assets over any other class of stock of the Company and which
      is
      not subject to redemption and (ii) shares of common stock of any successor
      or acquiring corporation received by or distributed to the holders of Common
      Stock of the Company in the circumstances contemplated by Section
      4.3.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    “Convertible
      Securities” shall mean evidences of indebtedness, shares of stock or other
      securities which are convertible into or exchangeable, with or without payment
      of additional consideration in cash or property, for shares of Common Stock,
      either immediately or upon the occurrence of a specified date or a specified
      event.

     

    “Current
      Warrant Price” shall mean $____ subject to any adjustments to such amount made
      in accordance with Section 4 hereof. 

     

    “Exchange
      Act” shall mean the Securities Exchange Act of 1934, as amended, or any
      successor federal statute, and the rules and regulations of the Commission
      thereunder, all as the same shall be in effect from time to time.

     

    “Exercise
      Period” shall mean the period during which this Warrant is exercisable pursuant
      to Section 2.1.

     

    “Expiration
      Date” shall mean November 1, 2010.

     

    “Fully
      Diluted Outstanding” shall mean, when used with reference to Common Stock, at
      any date as of which the number of shares thereof is to be determined, all
      shares of Common Stock Outstanding at such date and all shares of Common Stock
      issuable in respect of this Warrant, outstanding on such date, and other options
      or warrants to purchase, or securities convertible into, including without
      limitation the shares of Common Stock outstanding on such date which would
      be
      deemed out-stand-ing in accordance with GAAP for purposes of determining book
      value or net income per share.

     

    “GAAP”
      shall mean generally accepted accounting principles in the United States of
      America as from time to time in effect.

     

    “Holder”
      shall mean the Person in whose name the Warrant or Warrant Stock set forth
      herein is registered on the books of the Company maintained for such
      purpose.

     

    “Market
      Price” per Common Share means the average of the closing bid prices of the
      Common Shares as reported on the National Association of Securities Dealers
      Automated Quotation System for the National Market, (“NASDAQ”) or, if such
      security is not listed or admitted to trading on the NASDAQ, on the principal
      national security exchange or quotation system on which such security is quoted
      or listed or admitted to trading, or, if not quoted or listed or admitted to
      trading on any national securities exchange or quotation system, the closing
      bid
      price of such security on the over-the-counter market on the day in question
      as
      reported by the National Association of Security Dealers, Inc., or a similar
      generally accepted reporting service, as the case may be, for the five (5)
      trading days immediately preceding the date of determination.

     

    “Other
      Property” shall have the meaning set forth in Section 4.5.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    “Outstanding”
      shall mean, when used with reference to Common Stock, at any date as of which
      the number of shares thereof is to be determined, all issued shares of Common
      Stock, except shares then owned or held by or for the account of the Company
      or
      any subsidiary thereof, and shall include all shares issuable in respect of
      outstanding scrip or any certificates representing fractional interests in
      shares of Common Stock.

     

    “Person”
      shall mean any individual, sole proprie-tor-ship, partnership, joint venture,
      trust, incorporated organization, association, corporation, institution, public
      benefit corporation, entity or government (whether federal, state, county,
      city,
      municipal or otherwise, including, without limitation, any instrumentality,
      division, agency, body or department thereof).

     

    “Restricted
      Common Stock” shall mean shares of Common Stock which are, or which upon their
      issuance on the exercise of this Warrant would be, evidenced by a certifi-cate
      bearing the restrictive legend set forth in Section 9.1(a).

     

    “Securities
      Act” shall mean the Securities Act of 1933, as amended, or any successor federal
      statute, and the rules and regulations of the Commission thereunder, all as
      the
      same shall be in effect at the time.

     

    “Transfer”
      shall mean any disposition of any Warrant or Warrant Stock or of any interest
      in
      either thereof, which would constitute a sale thereof within the meaning of
      the
      Securities Act.

     

    “Transfer
      Notice” shall have the meaning set forth in Section 9.2.

     

    “Vesting
      Date” shall mean the date 91 days from the date of issuance of this
      Warrant.

     

    “Warrant
      Issuance Date” shall mean the date on which the Warrants are issued to the
      Holder.

     

    “Warrants”
      shall mean this Warrant and all warrants issued upon transfer, division or
      combination of, or in substitution for, any thereof. All Warrants shall at
      all
      times be identical as to terms and conditions and date, except as to the number
      of shares of Common Stock for which they may be exercised.

     

    “Warrant
      Price” shall mean an amount equal to (i) the number of shares of Common
      Stock being purchased upon exercise of this Warrant pursuant to Section 2.1,
      multiplied by (ii) the Current Warrant Price as of the date of such
      exercise.

     

    “Warrant
      Stock” shall mean the shares of Common Stock purchased by the holders of the
      Warrants upon the exercise thereof.

     

    
      	
              2.

            	
              EXERCISE
                OF WARRANT

            

    

     

    2.1. Manner
      of Exercise.
      From
      and after the Vesting Date unless cancelled prior to such date and until 5:00
      P.M., New York City time, on the Expiration Date, Holder may exercise this
      Warrant, on any Business Day, for all or any part of the number of shares of
      Common Stock purchasable hereunder.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    In
      order
      to exercise this Warrant, in whole or in part, Holder shall deliver to the
      Company at the office or agency designated by the Company pursuant to Section
      12, (i) a written notice of Holder’s election to exercise this Warrant,
      which notice shall specify the number of shares of Common Stock to be purchased,
      (ii) payment by cash, check or bank draft payable to the Company of the
      Warrant Price in cash or by wire transfer or cashier’s check drawn on a United
      States bank for all shares then being purchased and (iii) this Warrant.
      Such notice shall be substantially in the form of the subscription form
      appearing at the end of this Warrant as Exhibit
      1,
      duly
      executed by Holder or its agent or attorney. Upon receipt of the items referred
      to in clauses (i), (ii) and (iii) above, the Company shall, as promptly as
      practicable, and in any event within five (5) Business Days thereafter, execute
      or cause to be executed and deliver or cause to be delivered to Holder a
      certificate or certificates representing the aggregate number of full shares
      of
      Common Stock issuable upon such exercise, together with cash in lieu of any
      fraction of a share, as hereinafter provided. The stock certificate or
      certificates so deliv-ered shall be, to the extent possible, in such
      denomination or denominations as Holder shall request in the notice and shall
      be
      registered in the name of Holder or, subject to Section 9, such other name
      as
      shall be designated in the notice. This Warrant shall be deemed to have been
      exercised and such certificate or certificates shall be deemed to have been
      issued, and Holder or any other Person so designated to be named therein shall
      be deemed to have become a holder of record of such shares for all purposes,
      as
      of the date the Warrant has been exercised by payment to the Company of the
      Warrant Price. If this Warrant shall have been exercised in part, the Company
      shall, at the time of delivery of the certificate or certificates representing
      Warrant Stock, deliver to Holder a new Warrant evidencing the rights of Holder
      to purchase the unpurchased shares of Common Stock called for by this Warrant,
      which new Warrant shall in all other respects be identical with this Warrant.
      

     

    The
      Holder shall be entitled to exercise the Warrant notwithstanding the
      commencement of any case under 11 U.S.C.§
      101
      et seq.
      (the
“Bankruptcy Code”). In the event the Company is a debtor under the Bankruptcy
      Code, the Company hereby waives to the fullest extent permitted any rights
      to
      relief it may have under 11 U.S.C.§ 362
      in respect of the Holder’s exercise right. The Company hereby waives to the
      fullest extent permitted any rights to relief it may have under 11
      U.S.C.§ 362
      in respect of the exercise of the Warrant. The Company agrees, without cost
      or
      expense to the Holder, to take or consent to any and all action necessary to
      effectuate relief under 11 U.S.C.§ 362.

     

    2.2. Payment
      of Taxes and Charges.
      All
      shares of Common Stock issuable upon the exercise of this Warrant pursuant
      to
      the terms hereof shall be validly issued, fully paid and nonassessable, and
      without any preemptive rights. The Company shall pay all expenses in connection
      with, and all taxes and other governmental charges that may be imposed with
      respect to, the issue or delivery thereof.

     

    2.3. Fractional
      Shares.
      The
      Company shall not be required to issue a fractional share of Common Stock upon
      exercise of any Warrant. As to any fraction of a share which Holder would
      otherwise be entitled to purchase upon such exercise, the Company shall pay
      a
      cash adjustment in respect of such final fraction in an amount equal to the
      same
      fraction of the Market Price per share of Common Stock on the relevant exercise
      date.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    2.4. Continued
      Validity.
      A
      holder of shares of Common Stock issued upon the exercise of this Warrant,
      in
      whole or in part (other than a holder who acquires such shares after the same
      have been publicly sold pursuant to a Registration Statement under the
      Securities Act or sold pursuant to Rule 144 thereunder), shall continue to
      be
      entitled with respect to such shares to all rights to which it would have been
      entitled as Holder under Sections 9, 10 and 14 of this Warrant. The Company
      will, at the time of exercise of this Warrant, in whole or in part, upon the
      request of Holder, acknowledge in writing, in form reasonably satisfactory
      to
      Holder, its continuing obligation to afford Holder all such rights; provided,
      however,
      that if
      Holder shall fail to make any such request, such failure shall not affect the
      continuing obligation of the Company to afford to Holder all such
      rights.

     

    
      	
              3.

            	
              TRANSFER,
                DIVISION AND
                COMBINATION

            

    

     

    3.1. Transfer.
      Subject
      to compliance with Section 9, transfer of this Warrant and all rights hereunder,
      in whole or in part, shall be registered on the books of the Company to be
      maintained for such purpose, upon surrender of this Warrant at the principal
      office of the Company referred to in Section 2.1 or the office or agency
      desig-nated by the Company pursuant to Section 12, together with a written
      assignment of this Warrant substantially in the form of Exhibit
      2
      hereto
      duly executed by Holder or its agent or attorney. Upon such surren-der, the
      Company shall, subject to Section 9, execute and deliver a new Warrant or
      Warrants in the name of the assignee or assignees and in the denomi-na-tion
      specified in such instrument of assignment, and shall issue to the assignor
      a
      new Warrant evidencing the portion of this Warrant not so assigned, and this
      Warrant shall promptly be cancelled. A Warrant, if properly assigned in
      compliance with Section 9, may be exercised by a new Holder for the purchase
      of
      shares of Common Stock without having a new Warrant issued.

     

    3.2.  Division
      and Combination.
      Subject
      to Section 9, this Warrant may be divided or combined with other Warrants upon
      presentation hereof at the aforesaid office or agency of the Company, together
      with a written notice specifying the names and denominations in which new
      Warrants are to be issued, signed by Holder or its agent or attorney. Subject
      to
      compliance with Section 3.1 and with Section 9, as to any transfer which may
      be
      involved in such division or combination, the Company shall execute and deliver
      a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
      or combined in accordance with such notice.

     

    3.3. Expenses.
      The
      Company shall prepare, issue and deliver at its own expense the new Warrant
      or
      Warrants under this Section 3.

     

    3.4. Maintenance
      of Books.
      The
      Company agrees to maintain, at its aforesaid office or agency, books for the
      registration and the registration of transfer of the Warrants.

     

    
      	
              4.

            	
              ADJUSTMENTS

            

    

     

    The
      number of shares of Common Stock for which this Warrant is exercisable, or
      the
      price at which such shares may be purchased upon exercise of this Warrant,
      shall
      be subject to adjustment from time to time as set forth in this Section 4.
      The
      Company shall give Holder notice of any event described below which requires
      an
      adjustment pursuant to this Section 4 at the time of such event.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    4.1. Stock
      Dividends, Subdivisions and Combinations.
      If at
      any time the Company shall:

     

    (a) take
      a
      record of the holders of its Common Stock for the purpose of entitling them
      to
      receive a dividend payable in, or other distribution of, Additional Shares
      of
      Common Stock, 

     

    (b) subdivide
      its outstanding shares of Common Stock into a larger number of shares of Common
      Stock, or

     

    (c) combine
      its outstanding shares of Common Stock into a smaller number of shares of Common
      Stock, 

     

    then
      (i) the number of shares of Common Stock for which this Warrant is
      exercisable immediately after the occurrence of any such event shall be adjusted
      to equal the number of shares of Common Stock which a record holder of the
      same
      number of shares of Common Stock for which this Warrant is exercisable
      immediately prior to the occurrence of such event would own or be entitled
      to
      receive after the happen-ing of such event, and (ii) the Current Warrant
      Price shall be adjusted to equal (A) the Current Warrant Price multi-plied
      by the number of shares of Common Stock for which this Warrant is exercisable
      immediately prior to the adjustment divided by (B) the number of shares for
      which this Warrant is exercisable immediately after such
      adjustment.

     

    4.2. Other
      Provisions Applicable to Adjustments under this Section.
      The
      following provisions shall be applicable to the making of adjustments of the
      number of shares of Common Stock for which this Warrant is exercisable and
      the
      Current Warrant Price provided for in this Section 4:

     

    (a) When
      Adjustments to Be Made.
      The
      adjustments required by this Section 4 shall be made whenever and as often
      as
      any specified event requiring an adjustment shall occur. For the purpose of
      any
      adjustment, any specified event shall be deemed to have occurred at the close
      of
      business on the date of its occurrence. 

     

    (b) Fractional
      Interests.
      In
      computing adjust-ments under this Section 4, fractional interests in Common
      Stock shall be taken into account to the nearest 1/10th of a share.

     

    (c) When
      Adjustment Not Required.
      If the
      Company shall take a record of the holders of its Common Stock for the purpose
      of entitling them to receive a dividend or distribution or subscription or
      purchase rights and shall, thereafter and before the distribution to
      stock-holders thereof, legally abandon its plan to pay or deliver such dividend,
      distribution, subscription or purchase rights, then thereafter no adjustment
      shall be required by reason of the taking of such record and any such adjustment
      previously made in respect thereof shall be rescinded and annulled.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    (d) Challenge
      to Good Faith Determination.
      Whenever the Board of Directors of the Company shall be required to make a
      determination in good faith of the fair value of any item under this Section
      4,
      such determination may be challenged in good faith by the Holder, and any
      dispute shall be resolved by an investment banking firm of recognized national
      standing selected by the Holder and reasonably acceptable to the Company.

     

    (e) Proceeding
      Prior to Any Action Requiring Adjustment.
      As a
      condition precedent to the taking of any action which would require an
      adjustment pursuant to this Section 4, the Company shall take any action which
      may be necessary, including obtaining regulatory approvals or exemptions, in
      order that the Company may thereafter validly and legally issue as fully paid
      and nonassessable all shares of Common Stock which the Holder is entitled to
      receive upon exercise hereof. 

     

    4.3. Reorganization,
      Reclassification, Merger, Consolidation or Disposition of Assets.
      In case
      the Company shall reorganize its capital, reclassify its capital stock,
      consolidate or merge with or into another corporation (where the Company is
      not
      the surviving corporation or where there is a change in or distribution with
      respect to the Common Stock of the Company), or sell, transfer or otherwise
      dispose of all or substantially all its property, assets or business to another
      corporation and, pursuant to the terms of such reorganization, reclassification,
      merger, consolidation or disposition of assets, shares of common stock of the
      successor or acquiring corporation, or any cash, shares of stock or other
      securities or property of any nature what-so-ever (including warrants or other
      subscription or purchase rights) in addition to or in lieu of common stock
      of
      the successor or acquiring corporation (“Other Property”), are to be received by
      or distributed to the holders of Common Stock of the Company, then Holder shall
      have the right thereafter to receive, upon exercise of the Warrant, the number
      of shares of common stock of the successor or acquir-ing corporation or of
      the
      Company, if it is the surviving corpo-ration, and Other Property receivable
      upon
      or as a result of such reorganization, reclassification, merger, consolidation
      or disposition of assets by a holder of the number of shares of Common Stock
      for
      which this Warrant is exercisable imme-diately prior to such event. In case
      of
      any such reorgani-za-tion, reclassification, merger, consolidation or
      disposi-tion of assets, the successor or acquiring corporation (if other than
      the Company) shall expressly assume the due and punc-tual observance and
      performance of each and every covenant and condition of this Warrant to be
      performed and observed by the Company and all the obligations and liabilities
      here-under, subject to such modifications as may be deemed appropriate, subject
      to the Holder’s consent, in order to provide for adjustments of shares of Common
      Stock for which this Warrant is exer-cis-able which shall be as nearly
      equivalent as practicable to the adjustments provided for in this Section 4.
      For
      purposes of this Section 4.3, “common stock of the successor or acquiring
      corporation” shall include stock of such corpo-ra-tion of any class which is not
      preferred as to dividends or assets over any other class of stock of such
      corporation and which is not subject to redemption and shall also include any
      evidences of indebtedness, shares of stock or other securities which are
      convertible into or exchangeable for any such stock, either immediately or
      upon
      the arrival of a specified date or the happening of a specified event and any
      warrants or other rights to subscribe for or pur-chase any such stock. The
      foregoing provisions of this Section 4.3 shall similarly apply to successive
      reorganiza-tions, reclassifications, mergers, consolidations or disposition
      of
      assets.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    4.4. Other
      Action Affecting Common Stock.
      In case
      at any time or from time to time the Company shall take any action in respect
      of
      its Common Stock, other than any action taken in the ordinary course of the
      Company’s business or any action described in this Section 4, which would have a
      material adverse effect upon the rights of the Holder, the number of shares
      of
      Common Stock and/or the purchase price thereof shall be adjusted in such manner
      as may be equitable in the circumstances, as determined in good faith by an
      investment bank selected by Holder.

     

    4.5. Certain
      Limitations.
      Notwithstanding any-thing herein to the contrary, the Company agrees not to
      enter into any transaction which, by reason of any adjustment hereunder, would
      cause the Current Warrant Price to be less than the par value per share of
      Common Stock.

     

    4.6. No
      Voting Rights.
      This
      Warrant shall not entitle its Holder to any voting rights or other rights as
      a
      shareholder of the Company.

     

    
      	
              5.

            	
              NOTICES
                TO HOLDER

            

    

     

    5.1. Notice
      of Adjustments.
      Whenever the number of shares of Common Stock for which this Warrant is
      exercis-able, or whenever the price at which a share of such Common Stock may
      be
      purchased upon exercise of the Warrants, shall be adjusted pursuant to Section
      4, the Company shall forthwith prepare a certificate to be executed by an
      executive officer of the Company setting forth, in reasonable detail, the event
      requiring the adjustment and the method by which such adjustment was calculated,
      specifying the number of shares of Common Stock for which this Warrant is
      exercisable and describing the number and kind of any other shares of stock
      or
      Other Prop-erty for which this Warrant is exercisable, and any change in the
      purchase price or prices thereof, after giving effect to such adjustment or
      change. The Company shall promptly cause a signed copy of such certificate
      to be
      delivered to the Holder in accordance with Section 14.2. The Company shall
      keep
      at its office or agency designated pursuant to Section 12 copies of all such
      certificates and cause the same to be available for inspection at said office
      during normal business hours by the Holder, its representatives, or any
      prospective purchaser of a Warrant designated by the Holder.

     

    5.2. Notice
      of Corporate Action.
      If at
      any time

     

    (a) the
      Company shall take a record of the holders of its Common Stock for the purpose
      of entitling them to receive a dividend or other distribu-tion (whether in
      cash,
      or any right to subscribe for or purchase any evidences of its indebtedness,
      any
      shares of stock of any class or any other securities or property of any nature
      whatsoever, or to receive any warrants or other rights (including, without
      limitation, rights to subscribe for or purchase any evidences of its
      indebtedness, any shares of its stock or any other securities or property of
      any
      nature whatsoever), or

     

    (b) there
      shall be any capital reorganization of the Company, any reclassification or
      recapitalization of the capital stock of the Company or any consolidation or
      merger of the Company with, or any sale, transfer or other disposition of all
      or
      substantially all the property, assets or business of the Company to, another
      corporation, or

     

    (c) there
      shall be a voluntary or involuntary dissolution, liquidation or winding up
      of
      the Company; 

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    then,
      in
      any one or more of such cases, the Company shall give to Holder (i) at
      least thirty (30) Business Days’ prior written notice of the date on which a
      record date shall be selected for such divi-dend, distribution or right or
      for
      determining rights to vote in respect of any such reorganization,
      reclassifica-tion, merger, consolidation, sale, transfer, disposition,
      dissolution, liquidation or winding up, and (ii) in the case of any such
      reorganization, reclassification, merger, consolidation, sale, transfer,
      disposition, dissolution, liquida-tion or winding up, at least thirty (30)
      Business Days’ prior written notice of the date when the same shall take place.
      Such notice in accordance with the foregoing clause also shall specify
      (i) the date on which any such record is to be taken for the purpose of
      such dividend, distribution or right, the date on which the holders of Common
      Stock shall be entitled to any such dividend, distribution or right, and the
      amount and character thereof, and (ii) the date on which any such
      reorganization, reclassification, merger, consolidation, sale, transfer,
      disposition, dissolution, liquidation or winding up is to take place and the
      time, if any such time is to be fixed, as of which the holders of Common Stock
      shall be entitled to exchange their shares of Common Stock for securities or
      other property deliverable upon such reorganization, reclassification, merger,
      consolidation, sale, transfer, disposition, dissolution, liquidation or winding
      up. Each such written notice shall be sufficiently given if addressed to Holder
      at the last address of Holder appearing on the books of the Company and
      delivered in accor-dance with Section 14.2.

     

    A
      reclassification of the Common Stock (other than a change in par value, or
      from
      par value to no par value or from no par value to par value) into shares of
      Common Stock and shares of any other class of stock shall be deemed a
      distribution by the Company to the holders of its Common Stock of such shares
      of
      such other class of stock within the meaning of this Section and, if the
      outstanding shares of Common Stock shall be changed into a larger or smaller
      number of shares of Common Stock as a part of such reclassification, such change
      shall be deemed a subdivision or combination, as the case may be, of the
      outstanding shares of Common Stock within the meaning of Section
      4.1.

     

    
      	
              6.

            	
              NO
                IMPAIRMENT

            

    

     

    The
      Company shall not by any action, including, with-out limitation, amending its
      certificate of incorporation or through any reorganization, transfer of assets,
      consolida-tion, merger, dissolution, issue or sale of securities or any other
      voluntary action, avoid or seek to avoid the observance or performance of any
      of
      the terms of this Warrant, but will at all times in good faith assist in the
      carrying out of all such terms and in the taking of all such actions as may
      be
      necessary or appropriate to protect the rights of Holder against impairment.
      Without limiting the generality of the foregoing, the Company will (a) not
      increase the par value of any shares of Common Stock receivable upon the
      exercise of this Warrant above the amount payable there-for upon such exercise
      immediately prior to such increase in par value, (b) take all such action
      as may be necessary or appropriate in order that the Company may validly and
      legally issue fully paid and nonassessable shares of Common Stock upon the
      exercise of this Warrant, and (c) use its best efforts to obtain all such
      authorizations, exemptions or consents from any public regulatory body having
      jurisdiction thereof as may be necessary to enable the Company to perform its
      obligations under this Warrant.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    Upon
      the
      request of Holder, the Company will at any time during the period this Warrant
      is outstanding acknowl-edge in writing, in form reasonably satisfactory to
      Holder, the contin-u-ing validity of this Warrant and the obligations of the
      Company hereunder.

     

    
      	
              7.

            	
              RESERVATION
                AND AUTHORIZATION OF COMMON
                STOCK

            

    

     

    From
      and
      after the Closing Date, the Company shall at all times reserve and keep
      available for issue upon the exercise of Warrants such number of its authorized
      but unissued shares of Common Stock as will be sufficient to permit the exercise
      in full of all outstanding Warrants. All shares of Common Stock which shall
      be
      so issuable, when issued upon exercise of any Warrant and payment therefor
      in
      accordance with the terms of such Warrant, shall be duly and validly issued
      and
      fully paid and nonassessable, and not subject to preemptive rights. 

     

    Before
      taking any action which would cause an adjustment reducing the Current Warrant
      Price below the then par value, if any, of the shares of Common Stock issuable
      upon exercise of the Warrants, the Company shall take any corpo-rate action
      which may be necessary in order that the Company may validly and legally issue
      fully paid and non-assessable shares of such Common Stock at such adjusted
      Current Warrant Price.

     

    Before
      taking any action which would result in an adjustment in the number of shares
      of
      Common Stock for which this Warrant is exercisable or in the Current Warrant
      Price, the Company shall obtain all such authorizations or exemptions thereof,
      or consents thereto, as may be necessary from any public regulatory body or
      bodies having jurisdiction thereof.

     

    
      	
              8.

            	
              TAKING
                OF RECORD; STOCK AND WARRANT TRANSFER
                BOOKS

            

    

     

    In
      the
      case of all dividends or other distribu-tions by the Company to the holders
      of
      its Common Stock with respect to which any provision of Section 4 refers to
      the
      taking of a record of such holders, the Company will in each such case take
      such
      a record as of the close of business on a Business Day. The Company will not
      at
      any time close its stock transfer books or Warrant transfer books so as to
      result in preventing or delaying the exercise or transfer of any
      Warrant.

     

    
      	
              9.

            	
              RESTRICTIONS
                ON TRANSFERABILITY

            

    

     

    The
      Warrants and the Warrant Stock shall not be transferred, hypothecated or
      assigned before satisfaction of the conditions specified in this Section 9,
      which conditions are intended to ensure compliance with the provisions of the
      Securities Act with respect to the Transfer of any Warrant or any Warrant Stock.
      Holder, by acceptance of this Warrant, agrees to be bound by the provisions
      of
      this Section 9.

     

    9.1. Restrictive
      Legend.
      The
      Holder by accepting this Warrant and any Warrant Stock agrees that this Warrant
      and the Warrant Stock issuable upon exercise hereof may not be assigned or
      otherwise transferred unless and until (i) the Company has received an opinion
      of counsel for the Holder that such securities may be sold pursuant to an
      exemption from registration under the Securities Act or (ii) a registration
      statement relating to such securities has been filed by the Company and declared
      effective by the Commission.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    (a) Each
      certificate for Warrant Stock issuable hereunder shall bear a legend
      substantially worded as follows unless such securities have been sold pursuant
      to an effective registration statement under the Securities Act: 

     

    “The
      securities represented by this certificate have not been registered under the
      Securities Act of 1933, as amended (the “Act”) or any state securities laws. The
      securities may not be offered for sale, sold, assigned, offered, transferred
      or
      otherwise distributed for value except (i) pursuant to an effective registration
      statement under the Act or any state securities laws or (ii) pursuant to an
      exemption from registration or prospectus delivery requirements under the Act
      or
      any state securities laws in respect of which the Company has received an
      opinion of counsel satisfactory to the Company to such effect. Copies of the
      agreement covering both the purchase of the securities and restricting their
      transfer may be obtained at no cost by written request made by the holder of
      record of this certificate to the Secretary of the Company at the principal
      executive offices of the Company.” 

     

    (b) Except
      as
      otherwise provided in this Sec-tion 9, the Warrant shall be stamped or
      otherwise imprinted with a legend in substantially the following form:

     

    “This
      Warrant and the securities represented hereby have not been regis-tered under
      the Securities Act of 1933, as amended, or any state securities laws and may
      not
      be transferred in violation of such Act, the rules and regulations thereunder
      or
      any state securities laws or the provisions of this Warrant.” 

     

    9.2. Notice
      of Proposed Transfers.
      Prior to
      any Transfer or attempted Transfer of any Warrants or any shares of Restricted
      Common Stock, the Holder shall give five (5) days’ prior written notice (a
“Transfer Notice”) to the Company of Holder’s intention to effect such Transfer,
      describing the manner and circumstances of the proposed Transfer, and obtain
      from counsel to Holder an opinion that the proposed Transfer of such Warrants
      or
      such Restricted Common Stock may be effected without registration under the
      Securities Act or state securities laws. After the Company’s receipt of the
      Transfer Notice and opinion, such Holder shall thereupon be entitled to Transfer
      such Warrants or such Restricted Common Stock, in accordance with the terms
      of
      the Transfer Notice. Each certificate, if any, evidencing such shares of
      Restricted Common Stock issued upon such Transfer and the Warrant issued upon
      such Transfer shall bear the restrictive legends set forth in Section 9.1,
      unless in the opinion of such counsel such legend is not required in order
      to
      ensure compliance with the Securities Act. 

     

    9.3. Termination
      of Restrictions.
      Notwithstand-ing the foregoing provisions of Section 9, the restrictions imposed
      by this Section upon the transferability of the Warrants, the Warrant Stock
      and
      the Restricted Common Stock (or Common Stock issuable upon the exercise of
      the
      Warrants) and the legend requirements of Section 9.1 shall terminate as to
      any
      particular Warrant or share of Warrant Stock or Restricted Common Stock (or
      Common Stock issuable upon the exercise of the Warrants) (i) when and so
      long as such security shall have been effectively registered under the
      Securities Act and applicable state securities laws and disposed of pursuant
      thereto or (ii) when the Company shall have received an opinion of counsel
      that such shares may be transferred with-out registration thereof under the
      Securities Act and applicable state securities laws. Whenever the restrictions
      imposed by Section 9 shall terminate as to this Warrant, as hereinabove
      provided, the Holder hereof shall be entitled to receive from the Company upon
      written request of the Holder, at the expense of the Company, a new Warrant
      bearing the following legend in place of the restrictive legend set forth
      hereon:

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    “THE
      RESTRICTIONS ON TRANSFERABIL-ITY OF THE WITHIN WARRANT CONTAINED IN SECTION
      9
      HEREOF TERMINATED ON ________, 20__, AND ARE OF NO FURTHER FORCE AND EFFECT.”

     

    All
      Warrants issued upon registration of transfer, division or combination of,
      or in
      substitution for, any Warrant or Warrants entitled to bear such legend shall
      have a similar legend endorsed thereon. Whenever the restrictions imposed by
      this Section shall terminate as to any share of Restricted Common Stock, as
      hereinabove provided, the holder thereof shall be entitled to receive from
      the
      Company, at the Company’s expense, a new certificate representing such Common
      Stock not bearing the restrictive legends set forth in Section 9.1.

     

    9.4. Listing
      on Securities Exchange.
      If the
      Company shall list any shares of Common Stock on any securities exchange, it
      will, at its expense, list thereon, maintain and, when necessary, increase
      such
      listing of, all shares of Common Stock issued or, to the extent permissible
      under the applicable securities exchange rules, issuable upon the exercise
      of
      this Warrant so long as any shares of Common Stock shall be so listed during
      the
      Exercise Period.

     

    
      	
              10.

            	
              SUPPLYING
                INFORMATION

            

    

     

    The
      Company shall cooperate with Holder in supplying such information as may be
      reasonably necessary for Holder to complete and file any information reporting
      forms presently or hereafter required by the Commission as a condition to the
      availability of an exemption from the Securities Act for the sale of any Warrant
      or Restricted Common Stock.

     

    
      	
              11.

            	
              LOSS
                OR MUTILATION

            

    

     

    Upon
      receipt by the Company from Holder of evidence reasonably satisfactory to it
      of
      the ownership of and the loss, theft, destruction or mutilation of this Warrant
      and indemnity reasonably satisfactory to it (it being understood that the
      written agreement of the Holder shall be sufficient indemnity), and in case
      of
      mutilation upon surrender and cancellation hereof, the Company will execute
      and
      deliver in lieu hereof a new Warrant of like tenor to Holder; provided,
      in the
      case of mutilation, no indemnity shall be required if this Warrant in
      identifiable form is surrendered to the Company for cancellation.

     

    
      	
              12.

            	
              OFFICE
                OF THE COMPANY

            

    

     

    As
      long
      as any of the Warrants remain outstanding, the Company shall maintain an office
      or agency (which may be the principal executive offices of the Company) where
      the Warrants may be presented for exercise, registration of transfer, division
      or combination as provided in this Warrant, such office to be initially located
      at 500 North Broadway, Suite 204, Jericho, NY 11753, provided, however, that
      the
      Company shall provide prior written notice to Holder of a change in address
      no
      less than thirty (30) days prior to such change.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	
              13.

            	
              LIMITATION
                OF LIABILITY

            

    

     

    No
      provision hereof, in the absence of affirmative action by Holder to purchase
      shares of Common Stock, and no enumeration herein of the rights or privileges
      of
      Holder hereof, shall give rise to any liability of Holder for the purchase
      price
      of any Common Stock or as a stockholder of the Company, whether such liability
      is asserted by the Company or by creditors of the Company.

     

    
      	
              14.

            	
              MISCELLANEOUS

            

    

     

    14.1. Nonwaiver
      and Expenses.
      No
      course of deal-ing or any delay or failure to exercise any right hereunder
      on
      the part of Holder shall operate as a waiver of such right or otherwise
      prejudice Holder’s rights, powers or remedies, notwithstanding all rights
      hereunder terminate on the Expiration Date. If the Company fails to make, when
      due, any payments provided for hereunder, or fails to comply with any other
      provision of this Warrant, the Company shall pay to Holder such amounts as
      shall
      be sufficient to cover any direct and indirect losses, damages, costs and
      expenses including, but not limited to, reasonable attor-neys’ fees, including
      those of appellate proceedings, incurred by Holder in collecting any amounts
      due
      pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
      hereunder.

     

    14.2. Notice
      Generally.
      Except
      as may be otherwise provided herein, any notice or other communication or
      delivery required or permitted hereunder shall be in writing and shall be
      delivered personally or sent by certified mail, postage prepaid, or by a
      nationally recognized overnight courier service, and shall be deemed given
      when
      so delivered personally or by overnight courier service, or, if mailed, three
      (3) days after the date of deposit in the United States mails, as
      follows:

    

      
        	
                (a) 
                  
                   

                

              	
                
                  
                    
                      if
                        to the Company, to:

                    

                  

                

              	
                
                  bioMETRX,
                    Inc
                    
                    500
                      North Broadway, Suite 204

                    Jericho,
                      NY 11753

                    Attention:
                      Mark Basile

                    Phone:  (516)
                      937-2828

                    Fax:
(516)
                      937-2880

                  

                

              
	 	 	 
	 	with
                a copy to:	
                Sommer & Schneider LLP

                595 Stewart Avenue, Suite 710

                Garden City, NY 11530

                Attention: Joel C. Schneider, Esq.

                Phone: (516) 228-8181

                Fax: (516) 228-8211

              
	 	 	 
	(b)	if
                to the Holder to: 	Interactive
                Resources Group, Inc.
                
                1025
                  Greenwood Boulevard, Suite 351

                Lake
                  Mary, FL 32746

                Phone: (407)
                  585-8800

                Fax: (407)
                  585-8801

              
	 	 	 

      

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    The
      Company or the Holder may change the foregoing address by notice given pursuant
      to this Section 14.2.

    

    14.3. Successors
      and Assigns.
      Subject
      to the provisions of Sections 3.1 and 9, this Warrant and the rights evidenced
      hereby shall inure to the benefit of and be binding upon the successors of
      the
      Company and the successors and assigns of Holder. The provisions of this Warrant
      are intended to be for the benefit of all Holders from time to time of this
      Warrant and, with respect to Section 9 hereof, holders of Warrant Stock, and
      shall be enforceable by any such Holder or holder of Warrant Stock.

     

    14.4. Amendment.
      This
      Warrant and all other Warrants may be modified or amended or the provisions
      hereof waived only with the prior written consent of the Company and the Holder.
      

     

    14.5. Severability.
      Wherever possible, each provision of this Warrant shall be interpreted in such
      manner as to be effective and valid under applicable law, but if any provision
      of this Warrant shall be prohibited by or invalid under applicable law, such
      provision shall be ineffective to the extent of such prohibition or invalidity,
      without invalidating the remainder of such provision or the remaining provisions
      of this Warrant.

     

    14.6. Headings.
      The
      headings used in this Warrant are for the convenience of reference only and
      shall not, for any purpose, be deemed a part of this Warrant.

     

    14.7. Governing
      Law.
      This
      Warrant shall be governed by the laws of the State of New York, without regard
      to the provisions thereof relating to conflict of laws. The Company consents
      to
      the jurisdiction of the federal courts whose districts encompass any part
      ofNassau County, New York or the state courts of the State of New York sitting
      in the County of Nassau in connection with any dispute arising under this
      Warrant or any of the transactions contemplated hereby, and hereby waives,
      to
      the maximum extent permitted by law, any objection, including any objections
      based on forum
      non conveniens, to
      the
      bringing of any such proceeding in such jurisdictions.

    

    
      	
              15.

            	
              REGISTRATION
                RIGHTS.
                

            

    

     

    15.1.
       Piggyback
      Registration.
      If, on
      or prior to the one-year anniversary of the original issuance of this Warrant
      (and except for the Registration Statement to be filed for the First Montauk
      Investors), the Company shall determine to register any Common Stock under
      the
      Securities Act for sale in connection with a public offering of Common Stock
      (other than pursuant to an employee benefit plan or a merger, acquisition or
      similar transaction), the Company will give written notice thereof to Holder
      and
      will include in such Registration Statement any of the Registrable Shares which
      Holder may request be included (“Included Shares”) by a writing delivered to the
      Company within 15 days after the notice given by the Company to Holder;
      provided, however, that if the offering is to be firmly underwritten, and the
      representative of the underwriters of the offering refuse in writing to include
      in the offering all of the shares of Common Stock requested by the Company
      and
      others, the shares to be included shall be allocated first to the Company and
      any shareholder who initiated such Registration and then among the others based
      on the respective number of shares of Common Stock held by such persons. If
      the
      Company decides not to, and does not, file a Registration Statement with respect
      to such Registration, or after filing determines to withdraw the same before
      the
      effective date thereof, the Company will promptly so inform Holder, and the
      Company will not be obligated to complete the registration of the Included
      Shares included therein. 

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    15.2
      Certain
      Covenants.
      In
      connection with any Registration: 

     

     

    15.2.1
      The Company shall take all lawful action such that the Registration Statement,
      any amendment thereto and the prospectus forming a part thereof does not contain
      an untrue statement of a material fact or omit to state a material fact required
      to be stated therein or necessary to make the statements therein, in light
      of
      the circumstances under which they are made, not misleading. Upon becoming
      aware
      of the occurrence of any event or the discovery of any facts during the
      Registration Period that make any statement of a material fact made in the
      Registration Statement or the related prospectus untrue in any material respect
      or which material fact is omitted from the Registration Statement or related
      prospectus that requires the making of any changes in the Registration Statement
      or related prospectus so that it will not contain any untrue statement of a
      material fact or omit to state a material fact necessary to make the statements
      therein, in light of the circumstances under which they are made, not misleading
      (taking into account any prior amendments or supplements), the Company shall
      promptly notify Holder, and, as soon as reasonably practicable prepare (but
      in
      no event more than five business days in the case of a supplement or seven
      business days in the case of a post-effective amendment) and file with the
      SEC a
      supplement or post-effective amendment to the Registration Statement or the
      related prospectus or file any other required document so that, as thereafter
      delivered to a purchaser of Shares from Holder, such prospectus will not contain
      any untrue statement of a material fact or omit to state a material fact
      necessary to make the statements therein, in light of the circumstances under
      which they were made, not misleading. The Company shall use its reasonable
      best
      efforts to keep the Registration Statement effective at all times during the
      period continuing until the earliest of (i) the date that is nine months after
      the last day of the calendar month following the month in which the Registration
      Statement is declared effective, (ii) the date when the Holder may sell all
      Registrable Securities under Rule 144 without volume or other restrictions
      or
      limits or (iii) the date the Holder no longer owns any of the Registrable
      Securities,

     

    15.2.2
      At
      least three business days prior to the filing with the SEC of the Registration
      Statement (or any amendment thereto) or the prospectus forming a part thereof
      (or any supplement thereto), the Company shall provide draft copies thereof
      to
      Holder and shall consider incorporating into such documents such comments as
      Holder (and its counsel) may propose to be incorporated therein. Notwithstanding
      the foregoing, no prospectus supplement, the form of which has previously been
      provided to Holder, need be delivered in draft form to Holder.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    15.2.3
      The Company shall promptly notify Holder upon the occurrence of any of the
      following events in respect of the Registration Statement or the prospectus
      forming a part thereof: (i) the receipt of any request for additional
      information from the SEC or any other federal or state governmental authority,
      the response to which would require any amendments or supplements to the
      Registration Statement or related prospectus; (ii) the issuance by the SEC
      or
      any other federal or state governmental authority of any stop order suspending
      the effectiveness of the Registration Statement or the initiation of any
      proceedings for that purpose; or (iii) the receipt of any notification with
      respect to the suspension of the qualification or exemption from qualification
      of any of the Shares for sale in any jurisdiction or the initiation or
      threatening of any proceeding for such purpose.

     

    15.2.4 
      The
      Company shall furnish to Holder with respect to the Included Shares registered
      under the Registration Statement (and to each underwriter, if any, of such
      Shares) such number of copies of prospectuses and such other documents as Holder
      may reasonably request, in order to facilitate the public sale or other
      disposition of all or any of the Included Shares by Holder pursuant to the
      Registration Statement.

     

    15.2.5
      In
      connection with any registration pursuant to Section 15.2, the Company shall
      file or cause to be filed such documents as are required to be filed by the
      Company for normal Blue Sky clearance in states specified in writing by Holder;
      provided,
      however,
      that
      the Company shall not be required to qualify to do business or consent to
      service of process in any jurisdiction in which it is not now so qualified
      or
      has not so consented.

     

    15.2.6
      The Company shall bear and pay all expenses incurred by it and Holder (other
      than underwriting discounts, brokerage fees and commissions and fees and
      expenses of more than one law firm) in connection with the registration of
      the
      Shares pursuant to the Registration Statement. 

     

    15.2.7
      As
      a condition to including Registrable Shares in a Registration Statement, Holder
      must provide to the Company such information regarding itself, the Registrable
      Shares held by it and the intended method of distribution of such Shares as
      shall be required to effect the registration of the Registrable Shares and,
      if
      the offering is being underwritten, Holder must provide such powers of attorney,
      indemnities and other documents as may be reasonably requested by the managing
      underwriter.

     

    15.2.8 
      Following the effectiveness of the Registration Statement, upon receipt from
      the
      Company of a notice that the Registration Statement contains an untrue statement
      of material fact or omits to state any material fact required to be stated
      therein or necessary to make the statements therein not misleading in light
      of
      the circumstances under which they were made, Holder will immediately
      discontinue disposition of Included Shares pursuant to the Registration
      Statement until the Company notifies Holder that it may resume sales of Included
      Shares and, if necessary, provides to Holder copies of the supplemental or
      amended prospectus. 

     

    

    [SIGNATURE
      PAGE FOLLOWS]

    
 

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    IN
      WITNESS WHEREOF, the Company has caused this Warrant to be duly executed and
      its
      corporate seal to be impressed hereon and attested by its Secretary or an
      Assistant Secretary.

     

    Dated:
      October ___, 2006

     

    BIOMETRX,
      INC.

    

    

    

    By:___________________________

    Name:

    Title:
      

    Attest:

     

    

    By:______________________

    Name:
      

    Title:
      

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    EXHIBIT
      1

     

    SUBSCRIPTION
      FORM

     

    [To
      be
      executed only upon exercise of Warrant]

     

    The
      undersigned registered owner of this Warrant irrevocably exercises this Warrant
      for the purchase of ______ Shares of Common Stock of bioMETRX, Inc., and
      herewith makes payment therefor in cash or by check or bank draft made payable
      to the Company, all at the price and on the terms and conditions specified
      in
      this Warrant and requests that certificates for the shares of Common Stock
      hereby purchased (and any securities or other property issuable upon such
      exercise) be issued in the name of and delivered to _____________ whose address
      is _________________ and, if such shares of Common Stock shall not include
      all
      of the shares of Common Stock issuable as provided in this Warrant, that a
      new
      Warrant of like tenor and date for the balance of the shares of Common Stock
      issuable hereunder be delivered to the undersigned.

     

    _________________________________________ 

    (Name
      of
      Registered Owner)

    

    __________________________________________

    (Signature
      of Registered Owner)

    

    __________________________________________

    (Street
      Address)

    

    __________________________________________

    (City) (State)  
      (Zip
      Code)

     

    NOTICE: The
      signature on this subscription must correspond with the name as written upon
      the
      face of the within Warrant in every particular, without alteration or
      enlargement or any change whatsoever.

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    EXHIBIT
      2

     

    ASSIGNMENT
      FORM

     

    FOR
      VALUE
      RECEIVED the undersigned registered owner of this Warrant hereby sells, assigns
      and transfers unto the Assignee named below all of the rights of the undersigned
      under this Warrant, with respect to the number of shares of Common Stock set
      forth below:

     

    Name
      and Address of Assignee   No.
      of
      Shares of

     

    Common
      Stock

     

    and
      does
      hereby irrevocably constitute and appoint ________________________
      attorney-in-fact to register such transfer on the books of bioMETRX, Inc.
      maintained for the purpose, with full power of substitution in the
      premises.

     

    Dated:__________________   
Print
      Name:__________________________

     

    

     

    Signature:___________________________

     

    

     

    Witness:_____________________________

     

    

     

    NOTICE: The
      signature on this assignment must correspond with the name as written upon
      the
      face of the within Warrant in every particular, without alteration or
      enlargement or any change whatsoever.NEITHER
      THESE WARRANTS NOR THE COMMON STOCK ISSUABLE UPON EXERCISE OF THESE WARRANTS
      HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD,
      PLEDGED OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT
      FOR
      SUCH SECURITIES UNDER THE ACT OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION
      IS
      AVAILABLE.

     

    No.
      ___

     

     

    
      	Original Issuance: November
              ___,
              2006	Warrants
              _________

    

     

    BIOMETRX,
      INC.

     

    WARRANTS

     

    

     

    BioMetrx,
      Inc., a Delaware corporation (“BioMetrx”),
      certifies that, for value received, _______________, or registered assigns
      (the
“Holder”),
      is
      the owner of _________________ (_________) Warrants of BioMetrx (the
“Warrants”).
      Each
      Warrant entitles the Holder to purchase from BioMetrx at any time prior to
      the
      Expiration Date (as defined below) one share of the common stock of BioMetrx
      (the “Common
      Stock”)
      for
      $1.25 per share (the “Exercise
      Price”),
      on
      the terms and conditions hereinafter provided. The Exercise Price and the number
      of shares of Common Stock purchasable upon exercise of each Warrant are subject
      to adjustment as provided in this Certificate. The Warrants have been issued
      as
      part of an authorized class of 99,000 warrants of like tenor. 

     

    1.  Expiration
      Date; Exercise

     

    1.1
        Expiration
      Date.
      The
      Warrants shall expire on September 15, 2011 (the “Expiration
      Date”).

     

    1.2
        Manner
      of Exercise.
      The
      Warrants are exercisable, in whole or in part, by delivery to BioMetrx of the
      following (the “Exercise
      Documents”):
      (a)
      this Certificate (b) a written notice of election to exercise the Warrants;
      and
      (c) payment of the Exercise Price in cash or by check. Within three business
      days following receipt of the foregoing, BioMetrx shall execute and deliver
      to
      the Holder: (a) a certificate or certificates representing the aggregate number
      of shares of Common Stock purchased by the Holder, and (b) if less than all
      of
      the Warrants evidenced by this Certificate are exercised, a new certificate
      evidencing the Warrants not so exercised.

     

    1.3
        Automatic
      Exercise.
      Immediately before the expiration or termination of this Warrant, to the extent
      this Warrant is not previously exercised, and at such time the fair market
      value
      of one share of the Company's Common Stock subject to this Warrant is greater
      than the Exercise Price, then in effect as adjusted pursuant to this Warrant,
      this Warrant shall be deemed automatically exercised pursuant to Section 1.1
      above, even if not surrendered. For purposes of such automatic exercise, the
      fair market value of the Company's Common Stock upon such expiration shall
      be
      determined pursuant to Section 2.3 herein. To the extent this Warrant or any
      portion thereof is deemed automatically exercised pursuant to this Section
      1.3,
      the Company agrees to promptly notify the Holder of the number of shares of
      Common Stock, if any, the Holder hereof is to receive by reason of such
      automatic exercise and the Holder shall tender the Exercise Price to the Company
      within 10 days of receipt of such notice or forfeit the right to the Common
      Stock in connection with such automatic exercise.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

       

    

    1.4
        Warrant
      Exercise Limitation.
      Notwithstanding any other provision of this Certificate, or the total number
      of
      shares of Common Stock otherwise available for purchase by Holder hereunder,
      if
      as of the date of exercise BioMetrx has a class of securities registered under
      Section 12 of the Securities Exchange Act of 1934, as amended, Holder may not
      exercise any Warrants under this Section 1 if immediately following such
      exercise Holder would beneficially own 5% or more of the outstanding Common
      Stock of BioMetrx. For this purpose, a representation of the Holder that
      following such exercise it would not beneficially own 4.99% or more of the
      outstanding Common Stock of BioMetrx shall be conclusive and binding upon
      BioMetrx.

     

    2.  Adjustments
      of Exercise Price and Number and Kind of Conversion Shares

     

    2.1
        In
      the
      event that BioMetrx shall at any time hereafter (a) pay a dividend in Common
      Stock or securities convertible into Common Stock; (b) subdivide or split its
      outstanding Common Stock; (c) combine its outstanding Common Stock into a
      smaller number of shares; then the number of shares to be issued immediately
      after the occurrence of any such event shall be adjusted so that the Holder
      thereafter may receive the number of shares of Common Stock it would have owned
      immediately following such action if it had exercised the Warrants immediately
      prior to such action and the Exercise Price shall be adjusted to reflect such
      proportionate increases or decreases in the number of shares.

     

    2.2
        In
      case
      of any reclassification of the outstanding shares of Common Stock (other than
      a
      change covered by Section 2.1 hereof or a change which solely affects the par
      value of such shares) or in the case of any merger or consolidation or merger
      in
      which BioMetrx is not the continuing corporation and which results in any
      reclassification or capital reorganization of the outstanding shares), the
      Holder shall have the right thereafter (until the Expiration Date) to receive
      upon the exercise hereof, for the same aggregate Exercise Price payable
      hereunder immediately prior to such event, the kind and amount of shares of
      stock or other securities or property receivable upon such reclassification,
      capital reorganization, merger or consolidation, by a Holder of the number
      of
      shares of Common Stock obtainable upon the exercise of the Warrants immediately
      prior to such event; and if any reclassification also results in a change in
      shares covered by Section 2.1, then such adjustment shall be made pursuant
      to both this Section 2.2 and Section 2.1 (without duplication). The
      provisions of this Section 2.2 shall similarly apply to successive
      reclassifications, capital reorganizations and mergers or consolidations, sales
      or other transfers.

     

    2.3
        Certain
      Anti-Dilution Adjustments.
      If
      at any
      time while any portion of this Warrant remains outstanding, the Company shall
      issue shares of Common Stock (or rights, warrants, or other securities
      convertible into or exchangeable for shares of Common Stock, other than
      issuances covered by Sections 2.1 or 2.2 above, at a price per share (or having
      an exercise, conversion, or exchange price per share) less than the Exercise
      Price in effect as of the date of issuance of such shares or of such rights,
      warrants, or other convertible or exchangeable securities, then, and in each
      such case, the Exercise Price shall be reduced (but not increased) to a price
      determined by dividing (A) an amount equal to the sum of (x) the number of
      shares of Common Stock outstanding immediately prior to such issue (determined
      on a fully-diluted basis; i.e., treating as outstanding all shares of Common
      Stock issuable upon exercise, exchange or conversion of all outstanding options
      (to the extent then vested and exercisable), warrants, or other securities
      exercisable or exchangeable for or convertible into, directly or indirectly,
      shares of Common Stock) multiplied by the then existing Exercise Price, plus
      (y)
      the consideration, if any received by the Company upon such issue, by (B) the
      total number of shares of Common Stock outstanding immediately after such issue
      or sale (determined on a fully-diluted basis as aforesaid). For the purpose
      of
      determining the consideration received by the Company upon any such issue
      pursuant to clause (y) above, if the consideration received by the Company
      is
      other than cash, its value will be deemed its fair market value, which if not
      readily determinable shall be determined in good faith by the Board of Directors
      of the Company. An adjustment made pursuant to the paragraph shall be made
      on
      the next business day following the date on which any such issuance is made
      and
      shall be effective retroactively immediately after the close of business on
      such
      date. Notwithstanding anything contrary in this Section 2.3, there shall be
      no
      reduction to the Exercise Price pursuant to this Section with respect to (i)
      the
      issuance or sale of options to purchase shares of Common Stock to employees,
      consultants and directors, pursuant to a stock option plan approved by the
      Board
      of Directors, (ii) the issuance of securities pursuant to the conversion or
      exercise of convertible or exercisable securities as of the date of this
      Warrant, (as adjusted for recapitalizations, stock splits, and the like) which
      are currently outstanding as of the date of this Warrant or (iii) the
      issuance of securities as consideration for a bona fide business acquisition
      of
      or by the Company, whether by merger, consolidation, sale of assets, sale or
      exchange of stock or otherwise, which involves a third party which is not
      affiliated with the Company or its current stockholders or in a strategic
      allowance. 

     

    
      
         

      

      
        -
          2
          -

        
          

        

      

      
         

      

       

    

    2.4
        No
      Impairment.
      The
      Company will not, by amendment of its Certificate of Incorporation or any other
      organizational or registration rights documents of the Company, or through
      any
      reorganization, recapitalization, transfer of assets, consolidation, merger,
      dissolution, issue or sale of securities or any other voluntary action, seek
      to
      avoid the observance or performance of any of the terms to be observed or
      performed hereunder by the Company, but will at all times in good faith assist
      in the carrying out of all the provisions of this Section 2 and in the taking
      of
      all such action as may be necessary or appropriate in order to protect the
      rights of the holder of this Warrant against impairment

     

    3.  Reservation
      of Shares.
      BioMetrx shall at all times reserve and keep available out of its authorized
      but
      unissued shares of Common Stock, such number of shares of Common Stock as shall
      from time to time be issuable upon exercise of the Warrants. If at any time
      the
      number of authorized but unissued shares of Common Stock shall not be sufficient
      to permit the exercise of the Warrants, BioMetrx shall promptly seek such
      corporate action as may necessary to increase its authorized but unissued shares
      of Common Stock to such number of shares as shall be sufficient for such
      purpose.

     

    4.  Certificate
      as to Adjustments.
      In each
      case of any adjustment in the Exercise Price, or number or type of shares
      issuable upon exercise of these Warrants, the Chief Financial Officer of
      BioMetrx shall compute such adjustment in accordance with the terms of these
      Warrants and prepare a certificate setting forth such adjustment and showing
      in
      detail the facts upon which such adjustment is based, including a statement
      of
      the adjusted Exercise Price. BioMetrx shall promptly send (by facsimile and
      by
      either first class mail, postage prepaid or overnight delivery) a copy of each
      such certificate to the Holder.

     

    
      
         

      

      
        -
          3
          -

        
          

        

      

      
         

      

       

    

    5.  Loss
      or Mutilation.
      Upon
      receipt of evidence reasonably satisfactory to BioMetrx of the ownership of
      and
      the loss, theft, destruction or mutilation of this Certificate, and of indemnity
      reasonably satisfactory to it, and (in the case of mutilation) upon surrender
      and cancellation of these Warrants, BioMetrx will execute and deliver in lieu
      thereof a new Certificate of like tenor as the lost, stolen, destroyed or
      mutilated Certificate.

     

    6.  Representations
      and Warranties of BioMetrx.
      BioMetrx hereby represents and warrants to Holder that:

     

    6.1
        Due
      Authorization.
      All
      corporate action on the part of BioMetrx, its officers, directors and
      shareholders necessary for (a) the authorization, execution and delivery of,
      and
      the performance of all obligations of BioMetrx under, these Warrants, and (b)
      the authorization, issuance, reservation for issuance and delivery of all of
      the
      Common Stock issuable upon exercise of these Warrants, has been duly taken.
      These Warrants constitute a valid and binding obligation of BioMetrx enforceable
      in accordance with their terms, subject, as to enforcement of remedies, to
      applicable bankruptcy, insolvency, moratorium, reorganization and similar laws
      affecting creditors’ rights generally and to general equitable
      principles.

     

    6.2
        Organization.
      BioMetrx is a corporation duly organized, validly existing and in good standing
      under the laws of the State referenced in the first paragraph of this
      Certificate and has all requisite corporate power to own, lease and operate
      its
      property and to carry on its business as now being conducted and as currently
      proposed to be conducted.

     

    6.3
        Valid
      Issuance of Stock.
      Any
      shares of Common Stock issued upon exercise of these Warrants will be duly
      and
      validly issued, fully paid and non-assessable.

     

    6.4
        Governmental
      Consents.
      All
      consents, approvals, orders, authorizations or registrations, qualifications,
      declarations or filings with any federal or state governmental authority on
      the
      part of BioMetrx required in connection with the consummation of the
      transactions contemplated herein have been obtained.

     

    7.  Representations
      and Warranties of Holder.
      Holder
      hereby represents and warrants to BioMetrx that:

     

    7.1
        Holder
      is
      acquiring the Warrants for its own account, for investment purposes
      only.

     

    7.2
        Holder
      understands that an investment in the Warrants involves a high degree of risk,
      and Holder has the financial ability to bear the economic risk of this
      investment in the Warrants, including a complete loss of such investment. Holder
      has adequate means for providing for its current financial needs and has no
      need
      for liquidity with respect to this investment.

     

    
      
         

      

      
        -
          4
          -

        
          

        

      

      
         

      

       

    

    7.3
        Holder
      has such knowledge and experience in financial and business matters that it
      is
      capable of evaluating the merits and risks of an investment in the Warrants
      and
      in protecting its own interest in connection with this transaction.

     

    7.4
        Holder
      understands that the Warrants have not been registered under the Securities
      Act
      or under any state securities laws. Holder is familiar with the provisions
      of
      the Securities Act and Rule 144 thereunder and understands that the restrictions
      on transfer on the Warrants may result in Holder being required to hold the
      Warrants for an indefinite period of time.

     

    7.5
        Holder
      agrees not to sell, transfer, assign, gift, create a security interest in,
      or
      otherwise dispose of, with or without consideration (collectively, “Transfer”)
      any of
      the Warrants except pursuant to an effective registration statement under the
      Securities Act or an exemption from registration. As a further condition to
      any
      such Transfer, except in the event that such Transfer is made pursuant to an
      effective registration statement under the Securities Act, if in the reasonable
      opinion of counsel to BioMetrx any Transfer of the Warrants by the contemplated
      transferee thereof would not be exempt from the registration and prospectus
      delivery requirements of the Securities Act, BioMetrx may require the
      contemplated transferee to furnish BioMetrx with an investment letter setting
      forth such information and agreements as may be reasonably requested by BioMetrx
      to ensure compliance by such transferee with the Securities Act.

     

    8.  Notices
      of Record Date.

     

    In
      the
      event:

     

    8.1
        BioMetrx
      shall take a record of the holders of its Common Stock (or other stock or
      securities at the time receivable upon the exercise of these Warrants), for
      the
      purpose of entitling them to receive any dividend or other distribution, or
      any
      right to subscribe for or purchase any shares of stock of any class or any
      other
      securities or to receive any other right; or

     

    8.2
        of
      any
      consolidation or merger of BioMetrx with or into another corporation, any
      capital reorganization of BioMetrx, any reclassification of the capital stock
      of
      BioMetrx, or any conveyance of all or substantially all of the assets of
      BioMetrx to another corporation in which holders of BioMetrx’s stock are to
      receive stock, securities or property of another corporation; or

     

    8.3
        of
      any
      voluntary dissolution, liquidation or winding-up of BioMetrx; or

     

    8.4
        of
      any
      redemption or conversion of all outstanding Common Stock;

     

    
      
         

      

      
        -
          5
          -

        
          

        

      

      
         

      

       

    

    then,
      and
      in each such case, BioMetrx will mail or cause to be mailed to the Holder a
      notice specifying, as the case may be, (a) the date on which a record is to
      be
      taken for the purpose of such dividend, distribution or right, or (b) the date
      on which such reorganization, reclassification, consolidation, merger,
      conveyance, dissolution, liquidation, winding-up, redemption or conversion
      is to
      take place, and the time, if any is to be fixed, as of which the holders of
      record of Common Stock (or such stock or securities as at the time are
      receivable upon the exercise of these Warrants), shall be entitled to exchange
      their shares of Common Stock (or such other stock or securities), for securities
      or other property deliverable upon such reorganization, reclassification,
      consolidation, merger, conveyance, dissolution, liquidation or winding-up.
      BioMetrx shall use all reasonable efforts to ensure such notice shall be
      delivered at least 5 days prior to the date therein specified.

     

    9.  Registration
      Rights. 

     

    9.1
        Piggyback
      Registration.
      If
      BioMetrx shall determine to register any Common Stock under the Securities
      Act
      for sale in connection with a public offering of Common Stock (other than
      pursuant to an employee benefit plan or a merger, acquisition or similar
      transaction), BioMetrx will give written notice thereof to Holder and will
      include in such Registration Statement any of the Registrable Shares which
      Holder may request be included (“Included
      Shares”)
      by a
      writing delivered to BioMetrx within 15 days after the notice given by BioMetrx
      to Holder; provided, however, that if the offering is to be firmly underwritten,
      and the representative of the underwriters of the offering refuse in writing
      to
      include in the offering all of the shares of Common Stock requested by BioMetrx
      and others, the shares to be included shall be allocated first to BioMetrx
      and
      any shareholder who initiated such Registration and then among the others based
      on the respective number of shares of Common Stock held by such persons. If
      BioMetrx decides not to, and does not, file a Registration Statement with
      respect to such Registration, or after filing determines to withdraw the same
      before the effective date thereof, BioMetrx will promptly so inform Holder,
      and
      BioMetrx will not be obligated to complete the registration of the Included
      Shares included therein. 

     

    9.2
        Certain
      Covenants.
      In
      connection with any Registration: 

     

    9.2.1
        BioMetrx
      shall take all lawful action such that the Registration Statement, any amendment
      thereto and the prospectus forming a part thereof does not contain an untrue
      statement of a material fact or omit to state a material fact required to be
      stated therein or necessary to make the statements therein, in light of the
      circumstances under which they are made, not misleading. Upon becoming aware
      of
      the occurrence of any event or the discovery of any facts during the
      Registration Period that make any statement of a material fact made in the
      Registration Statement or the related prospectus untrue in any material respect
      or which material fact is omitted from the Registration Statement or related
      prospectus that requires the making of any changes in the Registration Statement
      or related prospectus so that it will not contain any untrue statement of a
      material fact or omit to state a material fact necessary to make the statements
      therein, in light of the circumstances under which they are made, not misleading
      (taking into account any prior amendments or supplements), BioMetrx shall
      promptly notify Holder, and, as soon as reasonably practicable prepare (but
      in
      no event more than five business days in the case of a supplement or seven
      business days in the case of a post-effective amendment) and file with the
      SEC a
      supplement or post-effective amendment to the Registration Statement or the
      related prospectus or file any other required document so that, as thereafter
      delivered to a purchaser of Shares from Holder, such prospectus will not contain
      any untrue statement of a material fact or omit to state a material fact
      necessary to make the statements therein, in light of the circumstances under
      which they were made, not misleading. BioMetrx shall use its reasonable best
      efforts to keep the Registration Statement effective at all times during the
      period continuing until the earliest of (i) the date that is nine months after
      the last day of the calendar month following the month in which the Registration
      Statement is declared effective, (ii) the date when the Holder may sell all
      Registrable Securities under Rule 144 without volume or other restrictions
      or
      limits or (iii) the date the Holder no longer owns any of the Registrable
      Securities,

     

    
      
         

      

      
        -
          6
          -

        
          

        

      

      
         

      

       

    

    9.2.2
        At
      least
      three business days prior to the filing with the SEC of the Registration
      Statement (or any amendment thereto) or the prospectus forming a part thereof
      (or any supplement thereto), BioMetrx shall provide draft copies thereof to
      Holder and shall consider incorporating into such documents such comments as
      Holder (and its counsel) may propose to be incorporated therein. Notwithstanding
      the foregoing, no prospectus supplement, the form of which has previously been
      provided to Holder, need be delivered in draft form to Holder.

     

    9.2.3
        BioMetrx
      shall promptly notify Holder upon the occurrence of any of the following events
      in respect of the Registration Statement or the prospectus forming a part
      thereof: (i) the receipt of any request for additional information from the
      SEC
      or any other federal or state governmental authority, the response to which
      would require any amendments or supplements to the Registration Statement or
      related prospectus; (ii) the issuance by the SEC or any other federal or state
      governmental authority of any stop order suspending the effectiveness of the
      Registration Statement or the initiation of any proceedings for that purpose;
      or
      (iii) the receipt of any notification with respect to the suspension of the
      qualification or exemption from qualification of any of the Shares for sale
      in
      any jurisdiction or the initiation or threatening of any proceeding for such
      purpose.

     

    9.2.4
        BioMetrx
      shall furnish to Holder with respect to the Included Shares registered under
      the
      Registration Statement (and to each underwriter, if any, of such Shares) such
      number of copies of prospectuses and such other documents as Holder may
      reasonably request, in order to facilitate the public sale or other disposition
      of all or any of the Included Shares by Holder pursuant to the Registration
      Statement.

     

    9.2.5
        In
      connection with any registration pursuant to Section 9.2, BioMetrx shall file
      or
      cause to be filed such documents as are required to be filed by BioMetrx for
      normal Blue Sky clearance in states specified in writing by Holder; provided,
      however,
      that
      BioMetrx shall not be required to qualify to do business or consent to service
      of process in any jurisdiction in which it is not now so qualified or has not
      so
      consented.

     

    9.2.6
        BioMetrx
      shall bear and pay all expenses incurred by it and Holder (other than
      underwriting discounts, brokerage fees and commissions and fees and expenses
      of
      more than one law firm) in connection with the registration of the Shares
      pursuant to the Registration Statement. 

     

    9.2.7
        As
      a
      condition to including Registrable Shares in a Registration Statement, Holder
      must provide to BioMetrx such information regarding itself, the Registrable
      Shares held by it and the intended method of distribution of such Shares as
      shall be required to effect the registration of the Registrable Shares and,
      if
      the offering is being underwritten, Holder must provide such powers of attorney,
      indemnities and other documents as may be reasonably requested by the managing
      underwriter.

     

    
      
         

      

      
        -
          7
          -

        
          

        

      

      
         

      

       

    

    9.2.8
        Following
      the effectiveness of the Registration Statement, upon receipt from BioMetrx
      of a
      notice that the Registration Statement contains an untrue statement of material
      fact or omits to state any material fact required to be stated therein or
      necessary to make the statements therein not misleading in light of the
      circumstances under which they were made, Holder will immediately discontinue
      disposition of Included Shares pursuant to the Registration Statement until
      BioMetrx notifies Holder that it may resume sales of Included Shares and, if
      necessary, provides to Holder copies of the supplemental or amended prospectus.
      

     

    9.3
        Rule
      144.
      With a view to making available to Holder the benefits of Rule 144, BioMetrx
      agrees, during the period from September 30, 2008 until September 30, 2009,
      unless the shares issuable to the Holder may be sold pursuant to an effective
      Registration Statement, to:

     

    9.3.1
        comply
      with the provisions of paragraph (c)(1) of Rule 144; and

     

    9.3.2
        file
      with
      the SEC in a timely manner all reports and other documents required to be filed
      by BioMetrx pursuant to Section 13 or 15(d) under the Exchange Act; and, if
      at
      any time it is not required to file such reports but in the past had been
      required to or did file such reports, it will, upon the request of a Holder,
      make available other information as required by, and so long as necessary to
      permit sales of its Shares pursuant to, Rule 144.

     

    9.4
        BioMetrx
      Indemnification.
      BioMetrx agrees to indemnify and hold harmless Holder, and its officers,
      directors and agents, and each person, if any, who controls Holder within the
      meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act
      from and against any and all losses, claims, damages and liabilities caused
      by
      (i) any violation or alleged violation by BioMetrx of the Securities Act,
      Exchange Act, any state securities laws or any rule or regulation promulgated
      under the Securities Act, Exchange Act or any state securities laws, (ii) any
      untrue statement or alleged untrue statement of a material fact contained in
      any
      registration statement or prospectus relating to the Included Shares (as amended
      or supplemented if BioMetrx shall have furnished any amendments or supplements
      thereto) or any preliminary prospectus, or (iii) caused by any omission or
      alleged omission to state therein a material fact required to be stated therein
      or necessary to make the statements therein not misleading in light of the
      circumstances under which they were made, except insofar as such losses, claims,
      damages or liabilities are caused by any such untrue statement or omission
      or
      alleged untrue statement or omission based upon information furnished in writing
      to BioMetrx by Holder or on Holder’s behalf expressly for use
      therein.

     

    9.5
        Holder
      Indemnification.
      Holder
      agrees to indemnify and hold harmless BioMetrx, its officers, directors and
      agents and each person, if any, who controls BioMetrx within the meaning of
      either Section 15 of the Securities Act or Section 20 of the Exchange Act to
      the
      same extent as the foregoing indemnity from BioMetrx to Holder, but only with
      respect to information furnished in writing by Holder or on Holder’s behalf
      expressly for use in any registration statement or prospectus relating to the
      Registrable Shares, or any amendment or supplement thereto, or any preliminary
      prospectus. Notwistanding anything to the contrary contained herein, holder’s
      obligation to indemnify shall not be in an amount in excess of the net proceeds
      received by the holder from the same of the Registration Securities in the
      offering in which the indemnification claim relates.

     

    
      
         

      

      
        -
          8
          -

        
          

        

      

      
         

      

       

    

    9.6
        Indemnification
      Procedures.
      In case
      any proceeding (including any governmental investigation) shall be instituted
      involving any person in respect of which indemnity may be sought pursuant to
      this Section 9, such person (an “Indemnified
      Party”)
      shall
      promptly notify the person against whom such indemnity may be sought (the
“Indemnifying
      Party”)
      in
      writing and the Indemnifying Party shall assume the defense thereof, including
      the employment of counsel reasonably satisfactory to such Indemnified Party,
      and
      shall assume the payment of all fees and expenses; provided that the failure
      of
      any Indemnified Party so to notify the Indemnifying Party shall not relieve
      the
      Indemnifying Party of its obligations hereunder except to the extent (and only
      to the extent that) that the Indemnifying Party is materially prejudiced by
      such
      failure to notify. In any such proceeding, any Indemnified Party shall have
      the
      right to retain its own counsel, but the fees and expenses of such counsel
      shall
      be at the expense of such Indemnified Party unless (i) the Indemnifying Party
      and the Indemnified Party shall have mutually agreed to the retention of such
      counsel or (ii) in the reasonable judgment of such Indemnified Party
      representation of both parties by the same counsel would be inappropriate due
      to
      actual or potential differing interests between them. It is understood that
      the
      Indemnifying Party shall not, in connection with any proceeding or related
      proceedings in the same jurisdiction, be liable for the reasonable fees and
      expenses of more than one separate firm of attorneys (in addition to any local
      counsel) at any time for all such Indemnified Parties (including in the case
      of
      Holder, all of its officers, directors and controlling persons) and that all
      such fees and expenses shall be reimbursed as they are incurred. In the case
      of
      any such separate firm for the Indemnified Parties, the Indemnified Parties
      shall designate such firm in writing to the Indemnifying Party. The Indemnifying
      Party shall not be liable for any settlement of any proceeding effected without
      its written consent (which consent shall not be unreasonably withheld or
      delayed), but if settled with such consent, or if there be a final judgment
      for
      the plaintiff, the Indemnifying Party shall indemnify and hold harmless such
      Indemnified Parties from and against any loss or liability (to the extent stated
      above) by reason of such settlement or judgment. No Indemnifying Party shall,
      without the prior written consent of the Indemnified Party, effect any
      settlement of any pending or threatened proceeding in respect of which any
      Indemnified Party is or could have been a party and indemnity could have been
      sought hereunder by such Indemnified Party, unless such settlement includes
      an
      unconditional release of such Indemnified Party from all liability arising
      out
      of such proceeding.

     

    9.7
        Contribution.
      To the
      extent any indemnification by an Indemnifying Party is prohibited or limited
      by
      law, the Indemnifying Party agrees to make the maximum contribution with respect
      to any amounts for which, he, she or it would otherwise be liable under this
      Section 9.6 to the fullest extent permitted by law; provided, however, that
      (i)
      no contribution shall be made under circumstances where a party would not have
      been liable for indemnification under this Section 9.6 and (ii) no seller of
      Registrable Securities guilty of fraudulent misrepresentation (within the
      meaning used in the Securities Act) shall be entitled to contribution from
      any
      party who was not guilty of such fraudulent misrepresentation.

     

    10.  Nontransferability.
      Holder
      may not sell or transfer any Warrants to any person without registration under
      the Securities Act or providing an opinion of counsel reasonably acceptable
      to
      the Company that such transfer may lawfully be made without such registration.
      Any such purported transfer shall not be effective as between such purported
      transferee and BioMetrx. 

     

    
      
         

      

      
        -
          9
          -

        
          

        

      

      
         

      

       

    

    11.  Severability.
      If any
      term, provision, covenant or restriction of these Warrants is held by a court
      of
      competent jurisdiction to be invalid, void or unenforceable, the remainder
      of
      the terms, provisions, covenants and restrictions of these Warrants shall remain
      in full force and effect and shall in no way be affected, impaired or
      invalidated.

     

    12.  Notices.
      All
      notices, requests, consents and other communications required hereunder shall
      be
      in writing and shall be effective when delivered or, if delivered by registered
      or certified mail, postage prepaid, return receipt requested, shall be effective
      on the third day following deposit in United States mail: to the Holder, at
      the
      Holder’s address of record in the Company’s warrant register; and if addressed
      to BioMetrx, at BioMetrx, Inc., 500 North Broadway, Suite 204, Jericho, NY
      11753, or such other address as BioMetrx may designate in writing.

     

    13.  No
      Rights as Shareholder.
      The
      Holder shall have no rights as a shareholder of BioMetrx with respect to the
      shares issuable upon exercise of the Warrants until the receipt by BioMetrx
      of
      all of the Exercise Documents.

     

    14.  Waivers
      and Modifications.
      Any
      term or provision of this Warrant may be waived only by written document
      executed by the party entitled to the benefits of such terms or provisions.
      The
      terms and provisions of this Warrant may be modified or amended only by written
      agreement executed by the parties hereto. 

     

    15.  Governing
      Law.
      This
      Warrant will be governed by and construed in accordance with and governed by
      the
      laws of the State of New York, without giving effect to the conflict of law
      principles thereof.

     

    16.  Consent
      to Jurisdiction.
      Each
      party hereto
      hereby
      irrevocably and unconditionally submits to the jurisdiction of any federal
      or
      state court sitting in the County of New York in the State of New York and
      irrevocably agrees that all actions or proceedings arising out of or relating
      to
      this Note shall be litigated exclusively in such court. Each party hereto agrees
      not to commence any legal proceeding related hereto or thereto except in such
      courts. Each party hereto irrevocably waives any objection which it may now
      or
      hereafter have to the laying of the venue of any such proceeding in any such
      court and hereby further irrevocably and unconditionally waives and agrees
      not
      to plead or claim in any such court that any such action, suit or proceeding
      brought in any such court has been brought in an inconvenient forum. Each party
      hereto consents to process being served in any such action or proceeding by
      mailing a copy thereof by registered or certified mail.

     

    17.  Waiver
      of Jury Trial.
      EACH
      PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW,
      ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY
      OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS WARRANT. EACH
      PARTY HERETO (1) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY
      OF
      THE OTHER PARTIES HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT ANY OF THE
      OTHER
      PARTIES WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING
      WAIVER AND (2) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN
      INDUCED TO ENTER INTO THIS AGREEMENT, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS
      AND CERTIFICATIONS IN THIS SECTION 17.

     

    
      
         

      

      
        -
          10
          -

        
          

        

      

      
         

      

    

     

    IN
      WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
      duly
      authorized officer as of the date first set forth above.

    

    
      	 	 	 
	 	BioMetrx,
              Inc.
	 
 	 
 	 
 
	 	By:  	 
	 	
              
Mark
              Basile, Chief Executive Officer 
	 	Title 

    

     

    
      
         

      

      
        -
          11
          -

        
          

        

      

      
         

      

    

    EXHIBIT
      “A”

    NOTICE
      OF EXERCISE

    (To
      be signed only upon exercise of the Warrants)

     

     

    To: BioMetrx,
      Inc.

     

    The
      undersigned hereby elects to purchase shares of Common Stock (the “Warrant
      Shares”)
      of
      BioMetrx, Inc. (“BioMetrx”),
      pursuant to the terms of the enclosed warrant certificate (the “Certificate”).
      The
      undersigned tenders herewith payment of the exercise price pursuant to the
      terms
      of the Certificate. 

     

    The
      undersigned hereby represents and warrants to, and agrees with, BioMetrx as
      follows: 

     

    1. Holder
      is
      acquiring the Warrant Shares for its own account, for investment purposes
      only.

     

    2. Holder
      understands that an investment in the Warrant Shares involves a high degree
      of
      risk, and Holder has the financial ability to bear the economic risk of this
      investment in the Warrant Shares, including a complete loss of such investment.
      Holder has adequate means for providing for its current financial needs and
      has
      no need for liquidity with respect to this investment.

     

    3. Holder
      has such knowledge and experience in financial and business matters that it
      is
      capable of evaluating the merits and risks of an investment in the Warrant
      Shares and in protecting its own interest in connection with this
      transaction.

     

    4. Holder
      understands that the Warrant Shares have not been registered under the
      Securities Act or under any state securities laws. Holder is familiar with
      the
      provisions of the Securities Act and Rule 144 thereunder and understands that
      the restrictions on transfer on the Warrant Shares may result in Holder being
      required to hold the Warrant Shares for an indefinite period of
      time.

     

    5. Holder
      agrees not to sell, transfer, assign, gift, create a security interest in,
      or
      otherwise dispose of, with or without consideration (collectively, “Transfer”)
      any of
      the Warrant Shares except pursuant to an effective registration statement under
      the Securities Act or an exemption from registration. As a further condition
      to
      any such Transfer, except in the event that such Transfer is made pursuant
      to an
      effective registration statement under the Securities Act, if in the reasonable
      opinion of counsel to BioMetrx any Transfer of the Warrant Shares by the
      contemplated transferee thereof would not be exempt from the registration and
      prospectus delivery requirements of the Securities Act, BioMetrx may require
      the
      contemplated transferee to furnish BioMetrx with an investment letter setting
      forth such information and agreements as may be reasonably requested by BioMetrx
      to ensure compliance by such transferee with the Securities Act.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    Each
      certificate evidencing the Warrant Shares will bear the following
      legend:

     

    “THE
      SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
      SECURITIES ACT OF 1933 (THE “ACT”) OR ANY APPLICABLE STATE SECURITIES LAWS AND
      MAY NOT BE EXERCISED, SOLD, PLEDGED OR TRANSFERRED IN THE ABSENCE OF AN
      EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE ACT OR UNLESS
      AN
      EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE.

     

    6. Immediately
      following this exercise of Warrants, if as of the date of exercise BioMetrx
      has
      a class of securities registered under Section 12 of the Securities Exchange
      Act
      of 1934, as amended, the undersigned will not beneficially own five percent
      (5%)
      or more of the then outstanding Common Stock of BioMetrx (based on the number
      of
      shares outstanding set forth in the most recent periodic report filed by
      BioMetrx with the Securities and Exchange Commission and any additional shares
      which have been issued since that date of which Holder is aware have been
      issued).

     

     

     

    Number
      of
      Warrants Exercised: ______________

     

    

     

    Dated:
      ____________________   

    

    

    
      
         

      

      
        -
          2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}]]